Monoclonal gammopathy of undetermined significance laboratory findings: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ Monoclonal gammopathy of undetermined significance }} | {{ Monoclonal gammopathy of undetermined significance }} | ||
{{CMG}} | {{CMG}} {{AE}} {{OK}} | ||
==Overview== | ==Overview== | ||
Revision as of 13:49, 14 August 2018
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance laboratory findings On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance laboratory findings |
|
FDA on Monoclonal gammopathy of undetermined significance laboratory findings |
|
on Monoclonal gammopathy of undetermined significance laboratory findings |
|
Monoclonal gammopathy of undetermined significance laboratory findings in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance laboratory findings |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
Laboratory Findings
Patients may be diagnosed with MGUS if they fulfill the following three criteria:[1]
- A monoclonal paraprotein band less than 3 g/dl;
- Plasma cells less than 10% on bone marrow examination; and
- No evidence of bone lesions, anemia, hypercalcemia, or renal insufficiency related to the paraprotein.
Check the blood for hypercalcemia and deterioration in renal function, check the urine for Bence-Jones protein
References
- ↑ International Myeloma Working Group (2003). "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group". Br J Haematol. 121 (5): 749–57. PMID 12780789.